Beloranib - Chong Kun Dang/ Larimar Therapeutics
Alternative Names: 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate; Beloranib hemioxalate; CKD-732; TNP-470 analogue; ZGN-433; ZGN-440Latest Information Update: 05 Jun 2020
At a glance
- Originator Chong Kun Dang
- Developer Chong Kun Dang; Zafgen
- Class Antineoplastics; Cyclohexanes; Obesity therapies; Sesquiterpenes; Small molecules; Unsaturated fatty acids
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Obesity; Prader-Willi syndrome; Solid tumours
Most Recent Events
- 29 May 2020 Chondrial Therapeutics has merged with Zafgen to form Larimar Therapeutics
- 19 Jul 2016 Discontinued - Phase-I for Colorectal cancer (Combination therapy) in South Korea (IV)
- 19 Jul 2016 Discontinued - Phase-I for Solid tumours in South Korea (IV)